

A systematic review about *Streptococcus Pneumoniae* in children in mainland of China before the PCV13 was licensed

Expert Review of Vaccines

16, 997-1006

DOI: 10.1080/14760584.2017.1360771

Citation Report

#	ARTICLE	IF	CITATIONS
1	Serotype distribution of <i>Streptococcus pneumoniae</i> and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1453-1463.	1.4	24
2	Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of <i>Streptococcus pneumoniae</i> From Adults of Three Hospitals in Shanghai, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 407.	1.8	14
3	Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive <i>Streptococcus pneumoniae</i> isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability. <i>Expert Review of Vaccines</i> , 2019, 18, 89-94.	2.0	16
4	Serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease isolates from children in mainland China—a systematic review. <i>Brazilian Journal of Microbiology</i> , 2020, 51, 665-672.	0.8	9
5	Serotype distribution of <i>Streptococcus pneumoniae</i> among healthy carriers and clinical patients: a systematic review from Iran. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 2257-2267.	1.3	8
6	A Systematic Review and Meta-Analysis of Serotype Distribution of <i>Streptococcus Pneumoniae</i> in Iran: Practical Evidence to Optimizing Local Vaccination Protocols. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, 304-310.	0.4	0
7	Immunogenicity and safety of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 2–5 years in China. <i>Vaccine</i> , 2021, 39, 3428-3434.	1.7	4
8	GtfA Interacting with GtfB is Required for PsrP Glycosylation in <i>Streptococcus pneumoniae</i> . <i>Jundishapur Journal of Microbiology</i> , 2018, In Press, .	0.2	1
9	A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. <i>Vaccine</i> , 2021, 39, 6947-6955.	1.7	1
10	Serotypic distribution and antimicrobial resistance of <i>Streptococcus pneumoniae</i> in Chinese children under 5 years after the introduction of the 13-valent conjugate pneumococcal vaccine: protocol for a scoping review. <i>F1000Research</i> , 2020, 9, 221.	0.8	0
11	Effect of pneumococcal conjugate vaccine availability on <i>Streptococcus pneumoniae</i> infections and genetic recombination in Zhejiang, China from 2009 to 2019. <i>Emerging Microbes and Infections</i> , 2022, 11, 606-615.	3.0	7
13	Immunogenicity and Safety of a Novel 13-Valent Pneumococcal Vaccine in Healthy Chinese Infants and Toddlers. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	1
14	Molecular epidemiology of <i>Streptococcus pneumoniae</i> isolated from children with community-acquired pneumonia under 5 years in Chengdu, China. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	1
15	The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
16	Research Progress on <i>Mycoplasma pneumoniae</i> Pneumonia and <i>Streptococcus pneumoniae</i> Pneumonia in Children. <i>Advances in Clinical Medicine</i> , 2023, 13, 5262-5267.	0.0	0